Grass pollen allergoids - Allergopharma

Drug Profile

Grass pollen allergoids - Allergopharma

Alternative Names: Allergovit 6 Grasses

Latest Information Update: 08 Dec 2015

Price : $50

At a glance

  • Originator Allergopharma
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Grass pollen hypersensitivity
  • Phase III Rhinoconjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 19 Nov 2015 Phase-III clinical trials in Seasonal allergic rhinitis (Prevention of relapse) in Germany (SC) (EudraCT2015-002409-13)
  • 19 Nov 2015 Phase-III clinical trials in Rhinoconjunctivitis (Prevention of relapse) in Germany (SC) (EudraCT2015-002409-13)
  • 19 Sep 2013 Allergopharma completes a phase II trial in Grass pollen hypersensitivity and Seasonal allergic rhinitis in Germany (EudraCT2012-001914-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top